Ilonov

1. Executive Summary (Confidence: High)

Ilonov, founded in 2020 as a spin-off of the European Diabetes Study Center (CeeD) in Strasbourg, is a French-Swiss biotech entity uniquely positioned at the forefront of the longevity ecosystem. The organization treats skeletal muscle as an endocrine organ, harvesting the therapeutic potential of myokines—hormones naturally secreted during exercise—to regulate systemic metabolism. Their primary mission is to alleviate the burden of daily diabetes management and eliminate severe age-related complications like renal failure. As of March 2025, Ilonov has joined the BaseLaunch portfolio and entered a research collaboration with a leading pharmaceutical partner to explore the biological mechanisms of their lead candidate, ILV-001. This strategic shift aims to validate the "muscle-pancreas crosstalk" as a major new therapeutic domain for chronic diseases and longevity.